BACKGROUND: Patients with aggressive lymphoma achieving complete remission (CR) after first-line combination chemotherapy undergo regular surveillance to detect relapse. Current international guidelines recommend routine follow-up blood tests in this context, but evidence supporting this practice is limited. METHODS: We conducted a multi-centre retrospective analysis of all patients diagnosed with aggressive lymphoma treated with curative-intent chemotherapy who achieved CR for at least 3 months between 2000 and 2015. An abnormal blood test was defined as any new and unexplained abnormality for full blood examination, lactate dehydrogenase or erythrocyte sedimentation rate. RESULTS: Three hundred and forty-six patients attended a total of 3...
We sequentially studied bone marrow (BM) samples of 25 patients in complete remission of an acute ly...
Objective: Our aim was to retrospectively assess the role of routine CT scans within the first year ...
A specific predictor during routine follow-up to ascertain risk for postautologous peripheral blood ...
Surveillance computed tomography (CT) is usual practice for patients with aggressive non-Hodgkin lym...
After first-line therapy, patients with Hodgkin and aggressive non-Hodgkin lymphomas are followed cl...
Background: Serum lactate dehydrogenase is a non-specific marker for lymphoma whose ...
To access publisher's full text version of this article click on the hyperlink belowRelapse constitu...
BackgroundAlthough many patients with follicular lymphoma (FL) undergo routine radiographic surveill...
Item does not contain fulltextHigh-dose chemotherapy followed by autologous stem cell transplantatio...
The optimal follow-up care for relapse detection in acute myeloid leukemia (AML) patients in first r...
Background: The impact of active surveillance, comprising an annual CT scan and bone marrow biopsies...
Purpose: Molecular diagnostics and early assessment of treatment response that use methodologies cap...
Purpose Physical examinations and annual mammography (minimal follow-up) are as effective as laborat...
PURPOSE: Routine imaging for diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) ...
BACKGROUND:Sensitive methods for detecting residual disease may complement conventional morphology w...
We sequentially studied bone marrow (BM) samples of 25 patients in complete remission of an acute ly...
Objective: Our aim was to retrospectively assess the role of routine CT scans within the first year ...
A specific predictor during routine follow-up to ascertain risk for postautologous peripheral blood ...
Surveillance computed tomography (CT) is usual practice for patients with aggressive non-Hodgkin lym...
After first-line therapy, patients with Hodgkin and aggressive non-Hodgkin lymphomas are followed cl...
Background: Serum lactate dehydrogenase is a non-specific marker for lymphoma whose ...
To access publisher's full text version of this article click on the hyperlink belowRelapse constitu...
BackgroundAlthough many patients with follicular lymphoma (FL) undergo routine radiographic surveill...
Item does not contain fulltextHigh-dose chemotherapy followed by autologous stem cell transplantatio...
The optimal follow-up care for relapse detection in acute myeloid leukemia (AML) patients in first r...
Background: The impact of active surveillance, comprising an annual CT scan and bone marrow biopsies...
Purpose: Molecular diagnostics and early assessment of treatment response that use methodologies cap...
Purpose Physical examinations and annual mammography (minimal follow-up) are as effective as laborat...
PURPOSE: Routine imaging for diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) ...
BACKGROUND:Sensitive methods for detecting residual disease may complement conventional morphology w...
We sequentially studied bone marrow (BM) samples of 25 patients in complete remission of an acute ly...
Objective: Our aim was to retrospectively assess the role of routine CT scans within the first year ...
A specific predictor during routine follow-up to ascertain risk for postautologous peripheral blood ...